New drug combo trial aims to extend life for advanced lung cancer patients
NCT ID NCT07376382
Summary
This study is testing whether adding a new drug called SYS6010 to the standard medication osimertinib works better for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 450 participants will be randomly assigned to receive either the new combination or the standard drug alone. The main goal is to see if the combination can delay cancer growth longer and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.